Caris Life Sciences Inks CDx Collaboration With Debiopharm

May 30, 2019

NEW YORK (GenomeWeb) – Caris Life Sciences today announced a strategic collaboration with Debiopharm International to develop a companion diagnostic for an oncology drug being developed by the Swiss biopharmaceuticals firm.

The firms will use Caris' Molecular Intelligence (MI) Transcriptome assay for mRNA analysis to detect rare fibroblast growth factor receptor (FGFR) fusions and identify eligible patients for Debiopharm's FUZE phase II clinical trial of Debio 1347, a selective FGFR inhibitor.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Menu

Caris Life Sciences Inks CDx Collaboration With Debiopharm

To read the full story....

Breaking News

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Roche's Rozlytrek Nets Japanese Approval in NTRK-Positive Pan Cancer Indication

European Commission Approves Lynparza for Advanced Ovarian Cancer With BRCA Mutations

FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

Multi-Gene Panel Testing Finds Pathogenic Variant Carriers Missed Under Current Testing Guidelines

Saga Diagnostics Raises $4.2M

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

What's Popular?

Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms

Wake Forest Researchers Learn From Patient Data in Offering Precision Oncology Broadly

ASCO Data Pushes Boundaries for Genomic Testing in Localized Breast Cancer

Japan's National Cancer Center Adopts Qiagen Bioinformatics Platform for Precision Med Program

Roche's Rozlytrek Nets Japanese Approval in NTRK-Positive Pan Cancer Indication

Sponsorships